535 related articles for article (PubMed ID: 16949481)
1. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
[TBL] [Abstract][Full Text] [Related]
2. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
Roriz R; de Gevigney G; Finet G; Nantois-Collet C; Borch KW; Amiel M; Beaune J
J Radiol; 1999 Jul; 80(7):727-32. PubMed ID: 10431273
[TBL] [Abstract][Full Text] [Related]
4. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
[TBL] [Abstract][Full Text] [Related]
5. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
Liss P; Persson PB; Hansell P; Lagerqvist B
Kidney Int; 2006 Nov; 70(10):1811-7. PubMed ID: 17003814
[TBL] [Abstract][Full Text] [Related]
6. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
[TBL] [Abstract][Full Text] [Related]
7. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
[TBL] [Abstract][Full Text] [Related]
8. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
[TBL] [Abstract][Full Text] [Related]
9. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
Sutton AG; Ashton VJ; Campbell PG; Price DJ; Hall JA; de Belder MA
Catheter Cardiovasc Interv; 2002 Nov; 57(3):346-52. PubMed ID: 12410513
[TBL] [Abstract][Full Text] [Related]
11. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
[TBL] [Abstract][Full Text] [Related]
13. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
[TBL] [Abstract][Full Text] [Related]
14. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
Bertrand ME; Esplugas E; Piessens J; Rasch W
Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
McCullough PA; Bertrand ME; Brinker JA; Stacul F
J Am Coll Cardiol; 2006 Aug; 48(4):692-9. PubMed ID: 16904536
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
[TBL] [Abstract][Full Text] [Related]
17. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
Barrett BJ; Katzberg RW; Thomsen HS; Chen N; Sahani D; Soulez G; Heiken JP; Lepanto L; Ni ZH; Ni ZH; Nelson R
Invest Radiol; 2006 Nov; 41(11):815-21. PubMed ID: 17035872
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
Rudnick MR; Davidson C; Laskey W; Stafford JL; Sherwin PF;
Am Heart J; 2008 Oct; 156(4):776-82. PubMed ID: 18946896
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxic effects in high-risk patients undergoing angiography.
Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
[TBL] [Abstract][Full Text] [Related]
20. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy.
Adolph E; Holdt-Lehmann B; Chatterjee T; Paschka S; Prott A; Schneider H; Koerber T; Ince H; Steiner M; Schuff-Werner P; Nienaber CA
Coron Artery Dis; 2008 Sep; 19(6):413-9. PubMed ID: 18955835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
